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Abstract
Comparative genomic hybridization (CGH) studies
have provided a wealth of information on common
copy number aberrations in pancreatic cancer, but the
genes affected by these aberrations are largely un-
known. To identify putative amplification target genes
in pancreatic cancer, we performed a parallel copy
number and expression survey in 13 pancreatic cancer
cell lines using a 12,232-clone cDNA microarray, pro-
viding an average resolution of 300 kb throughout
the human genome. CGH on cDNA microarray allowed
highly accurate mapping of copy number increases
and resulted in identification of 24 independent am-
plicons, ranging in size from 130 kb to 11 Mb. Statis-
tical evaluation of gene copy number and expression
data across all 13 cell lines revealed a set of 105 genes
whose elevated expression levels were directly attrib-
utable to increased copy number. These included
genes previously reported to be amplified in cancer
as well as several novel targets for copy number alter-
ations, such as p21-activated kinase 4 (PAK4), which
was previously shown to be involved in cell migration,
cell adhesion, and anchorage-independent growth. In
conclusion, our results implicate a set of 105 genes
that is likely to be actively involved in the development
and progression of pancreatic cancer.
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Introduction
Nearly 30,000 new pancreatic cancer cases were diag-
nosed in the United States in 2001, representing about
2.3% of all new cancer cases [1]. Despite this relatively
low incidence, pancreatic cancer was the fourth common
cause of cancer deaths in the United States, with 5-year
survival rates of 3% to 5% [1,2]. The poor prognosis of
pancreatic cancer is largely due to the fact that the first
symptoms (e.g., jaundice caused by the growing tumor
obstructing the common bile duct, or abdominal and back
pain caused by perineural invasion in the celiac plexus)
come typically rather late in the disease progression. There-
fore, most pancreatic cancers have already metastasized and
are inoperable at the time of diagnosis [3,4].
There are several well-documented risk factors for the
development of pancreatic cancer, including smoking [5],
chronic pancreatitis [6], and a family history of pancreatic
cancer [7,8]. However, the genetic changes involved in the
pathogenesis of pancreatic cancer are not fully understood,
although the role of a few known oncogenes and tumor-
suppressor genes has been well established (reviewed in
Ref. [9]). Mutations leading to activation of the KRAS onco-
gene are the most common genetic changes in pancreatic
cancer occurring in nearly all primary tumors [9,10]. KRAS
mutations have been observed already in normal pancreas as
well as in noninvasive neoplastic precursor lesions, indicating
that they represent an early event in the pathogenesis of
pancreatic cancer [11]. Furthermore, overexpression of EGFR
and MYC, as well as inactivation of TP53 and MADH4, have
been frequently detected in pancreatic cancer [10,12–14]. In
addition to these alterations involving known oncogenes or
tumor-suppressor genes, cytogenetic and molecular cytoge-
netic studies have revealed frequent structural and numeric
chromosome abnormalities in pancreatic cancer. For example,
comparative genomic hybridization (CGH) analyses have indi-
cated common gains affecting chromosomes 7, 8q, 17q, 19q,
and 20q, and losses of 6q, 8p, 9p, and 18q in pancreatic
adenocarcinomas [15–19].
Recently, DNA microarray–based methods have been ap-
plied to the analysis of pancreatic cancer, mainly in an effort to
identify new diagnostic markers or targets for the development
of new therapies against pancreatic cancer [20–25]. These
studies have revealed a considerable number of differentially
expressed genes, the majority of which has not been previously
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implicated in pancreatic cancer. For example, Iacobuzio-
Donahue et al. [24] identified a set of more than 400 genes
that were differentially expressed in pancreatic cancer tis-
sues and cell lines as compared to normal pancreas. These
genes were linked to multiple cellular processes, such as
cell–cell and cell–matrix interactions, cytoskeletal remodel-
ing, proteolytic activity, and Ca2+ homeostasis. A set of 149
genes was more highly expressed in pancreatic cancers
compared with normal pancreas and contained 103 genes
that had not been previously reported in association with
pancreatic cancer [24]. However, the exact role of these
differentially expressed genes discovered by Iacobuzio-
Donahue et al. [24] and others in pancreatic cancer patho-
genesis remains to be elucidated.
In this study, we used a combination of CGH and cDNA
microarray technologies to specifically identify those gene
expression change events that were associated with gene
copy number alterations. Analysis of 13 pancreatic cancer
cell lines using a 12,232-clone cDNA microarray revealed
24 independent amplicons and a set of 105 genes whose
expression levels were directly attributable to increased copy
number. We hypothesize that these genes are likely to have
a central role in the pathogenesis of pancreatic cancer.
Materials and Methods
Cell Lines
Thirteen established cell lines derived from pancreatic
adenocarcinomas or their metastases (AsPC-1, BxPC-3,
Capan-1, Capan-2, CFPAC-1, HPAC, HPAF-II, Hs 700T,
Hs 766T, MIA PaCa-2, PANC-1, SU.86.86, and SW 1990)
were obtained from the American Type Culture Collection
(ATCC; Manassas, VA). The CFPAC-1 cell line originated
from a patient with cystic fibrosis. The cells were grown
under recommended culture conditions. Genomic DNA was
isolated using standard protocols and mRNA was extracted
with FastTrack 2.0 Kit (Invitrogen, Carlsbad, CA). Both DNA
and mRNA preparations were derived from a single harvest
of cells.
cDNA Microarray–Based Copy Number and Expression
Analyses
The overall experimental design consisted of two parallel
microarray experiments where gene copy numbers and gene
expression levels were measured in 13 pancreatic cancer
cell lines by using an identical cDNA microarray. The cDNA
microarray contained polymerase chain reaction (PCR)–
amplified inserts derived from a total of 12,232 cDNA clones,
representing 8881 different transcripts printed on poly-L-
lysine–coated glass slides as previously described [26,27]
(full description of the clones and their locations on the array
is provided at http://sigwww.cs.tut.fi/TICSP/Mahlamaki_
et_al_2003/). All experiments were performed using slides
from a single print set.
Copy number analyses were performed as previously
reported [28,29]. Briefly, genomic DNA from cell lines and
sex-matched normal human white blood cells were digested
for 14 to 18 hours with AluI and RsaI restriction enzymes
(Life Technologies, Inc., Rockville, MD) and purified by
phenol/chloroform extraction. Six micrograms of digested
cell line and normal DNA was labeled with Cy3-dUTP and
Cy5-dUTP (AmershamPharmacia, Piscataway, NJ), respec-
tively, using Bioprime Labeling kit (Life Technologies, Inc.).
The hybridization mixture, containing the labeled probes,
150 mg of CotI DNA (Life Technologies, Inc.), 300 mg of yeast
tRNA (Gibco/BRL, Gaithersburg, MD), as well as 60 mg each
of poly(dA) and poly(dT) in 3.4  SSC/0.3% sodium dodecyl
sulfate (SDS), was denatured at 100jC for 1.5 minutes, in-
cubated for 30 minutes at 37jC, and hybridized to a micro-
array slide at 65jC for 16 to 24 hours in a sealed humidified
chamber. The slides were then washed in 0.1% SDS,
0.5  SSC/0.01% SDS, and 0.06  SSC for 2 minutes
each. For expression analyses, a pool of mRNA derived
from all 13 cell lines was used as a common reference. Four
micrograms of cell line mRNA was labeled with Cy3-dUTP
and an equal amount of control mRNA was labeled with Cy5-
dUTP by use of oligo(dT)-primed polymerization by Super-
Script II reverse transcriptase (Life Technologies, Inc.). The
labeled cDNA were hybridized on microarrays as described
[27,29]. Briefly, they were combined with 12 mg of poly(dA)
(Pharmacia, Bridgewater, NJ), 6 mg of tRNA, and 10 mg of
Cot I DNA (Life Technologies, Inc.) in 0.25% SDS/2  SSC.
The probe mix was incubated at 98jC for 2 minutes and at
4jC for 10 seconds, and hybridized on a cDNA microarray.
Hybridization and subsequent washing were carried out as
described above for copy number analyses.
For both copy number and expression analyses, a laser
confocal scanner (Agilent Technologies, Palo Alto, CA) was
used to measure the fluorescence intensities at the target
locations. The fluorescent images from the test and control
hybridizations were scanned separately, and image analysis
was performed using the DeARRAY software [30]. After
background subtraction, the average intensity at each clone
in the test hybridization was divided by the average intensity
of the corresponding clone in the control hybridization.
Within-slide normalization for each cDNA and CGH micro-
array was performed using the Local Weighted Scatter Plot
Smoother (LOWESS) method [31,32] for each print tip
group. Fraction of data points used in local regression (f )
was 0.4 and other parameters were adjusted as suggested
by Cleveland [32]. After within-slide normalization, low qual-
ity measurements (i.e., copy number data with mean refer-
ence intensity less than 50 fluorescent units, and expression
data with both test and reference intensity less than 100
fluorescent units and/or with spot size less than 50 units)
were excluded from the analysis and were treated as missing
values. Self versus self experiments were performed to
ensure the performance of copy number and expression
hybridizations. In addition, 15 clones were printed as tripli-
cates on the microarray. Evaluation of data derived from
these 15 clones showed highly consistent results for each of
the 13 cell lines with standard deviations ranging between
0.01 and 0.346 and between 0.011 and 0.427, for copy
number and expression data, respectively (all original data
are available at http://sigwww.cs.tut.fi/TICSP/Mahlamaki_
et_al_2003/).
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Identification of Amplicons
The chromosome and base-pair positions for each cDNA
clone on the array were determined by using information from
the November 2002 freeze of the University of California
SantaCruz’sGoldenPathdatabase (www.genome.ucsc.edu)
as described [33]. This information was available for 10,389
clones, providing an average spacing of 308 kb throughout
the human genome. The CGH copy number data were
ordered according to the location of the clones along chro-
mosomes. Genes with copy number ratio >1.4 (representing
the upper 5% of the CGH ratios across all experiments) were
considered to be amplified. Two different criteria were used
to define amplicons. First, based on the fact that typical
amplicons span a large region of the genome, six (providing
an average coverage of 1.5 Mb) or more adjacent clones
were expected to show a copy number ratio >1.4. Secondly,
to avoid missing small amplicons or amplicons located in
regions of the genome with poorer-than-average clone cov-
erage, regions with at least three adjacent clones with a
copy number ratio >1.4 and no less than one clone with a
ratio >2.0 were also considered as amplicons. The amplicon
start and end positions were extended to include neighboring
nonamplified clones (ratio <1.4). The amplicon size determi-
nation was dependent on the local clone density.
Statistical Analyses
The influence of gene copy number on gene expression
level was evaluated as described [33,34]. Briefly, within-slide
normalized CGH and cDNA ratios in each cell line were log-
transformed and median-centered. Furthermore, cDNA data
were median-centered using values across 13 cell lines. For
each gene, the CGH data were represented by a vector that
was labeled ‘‘1’’ for amplification ratio >1.4 and ‘‘0’’ for no
amplification. Amplification was correlated with gene expres-
sion using the signal-to-noise statistics [33,34]. A weight wg
was calculated for each gene:
wg ¼ mg1 mg0rg1 þ rg0
where mg1,rg1 and mg0,rg0 denote the means and standard
deviations for the expression levels for amplified and non-
amplified cell lines, respectively. To assess the statistical
significance of each weight, 10,000 random permutations of
the label vector were performed. The probability that a gene
had a larger or equal weight by random permutation than
the original weight was denoted by a. A low a (<0.05)
indicates a strong association between gene expression
and amplification.
Results
A genome-wide copy number analysis was performed in 13
pancreatic cancer cell lines using CGH on a cDNA micro-
array containing 12,232 clones. Chromosomal and base-pair
locations were obtained for 10,389 clones, providing an
average spacing of 308 kb throughout the human genome.
The clone density varied considerably from one region of
the genome to another, with chromosome 19 showing the
highest clone density (on average, one clone per 80 kb) and
chromosome 13 having the poorest clone density (one clone
per 1 Mb). Evaluation of copy number changes as a function
of the genomic position of the clones revealed a total number
of 24 independent amplicons in the 13 cell lines (Table 1).
The number of amplicons varied from one cell line to another,
with Capan1 cells showing the highest number of amplicons
(8 of 24). The amplicons were located on 12 different
chromosomes with multiple separate amplicons observed
on chromosomes 15q, 17q, and 19. The use of base-pair
information allowed exact determination of the locations and
boundaries of each amplicon (Table 1). In several cases, the
CGH microarray analysis resulted in high-resolution map-
ping of amplicons previously detected by chromosomal CGH
(Figure 1A). The size of the amplicons ranged from 130 kb to
11 Mb, with an average of 2 Mb (Table 1), although it has to
be noted that this size determination was dependent on the
local clone density.
Next we analyzed the expression levels of the 12,232
cDNA clones in the 13 pancreatic cancer cell lines using an
identical cDNA microarray. Direct comparison between copy
number and expression levels in each cell line allowed
unambiguous identification of genes whose expression lev-
els were elevated due to increased copy number. For
example, annotation of CGH copy number information with
color-coded expression data revealed increased expression
of several highly amplified genes, such as FBL, PD2,
SUPT5H, and SARS2, located at the 19q13.1 region in the
PANC-1 cell line (Figure 1B). Although such annotation is
extremely effective in pinpointing putative amplification tar-
get genes in individual samples, it becomes progressively
more complicated when the number of genes and samples
to be analyzed increases. To facilitate the identification of
Table 1. Summary of Independent Amplicons in 13 Pancreatic Cancer Cell
Lines by CGH on cDNA Microarray.
Location Start (Mb) End (Mb) Size (Mb)
3p21 39.73 42.01 2.28
3q29 198.68 199.49 0.81
5p15.3 0.19 0.48 0.29
6p21 29.97 30.91 0.94
6p21 30.94 32.48 1.55
7q21 90.70 94.85 4.15
7q22 95.13 99.58 4.44
8q24 133.88 135.60 1.72
11q13 70.15 71.17 1.02
14q21 44.90 48.66 3.76
15q22 66.15 69.29 3.14
15q24 74.74 76.26 1.52
15q25 83.12 84.32 1.20
15q26 84.98 96.03 11.05
17q21 39.56 40.31 0.75
17q21 42.27 42.71 0.44
17q21 44.46 44.60 0.14
17q25 82.61 83.27 0.66
19p13.3 1.97 2.11 0.13
19q13.1 39.26 42.12 2.86
19q13.3 50.85 51.24 0.39
20q13.3 62.13 62.28 0.15
Xp22.3 2.72 11.76 9.05
Xq28 149.31 149.66 0.35
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possible amplification target genes, we applied a statistical
approach with random permutation tests to explore the
effects of gene copy number on gene expression levels
across all 13 cell lines. This analysis revealed a set of 105
genes, including 70 known genes, whose expression levels
were highly dependent on gene copy number (i.e., these
genes were activated by increased copy number in the
pancreatic cancer cell lines) (Table 2). The set included
genes previously shown to be amplified in human cancer
(e.g., MLN51) as well as known oncogenes (e.g., RAB4A,
member of the RAS oncogene family). In addition, 11 (16%)
of the 70 known genes (ARHGDIB, CLDN4, FBL, MCM7,
PSMC4, RELA, SIRT2, ST14, STK15, SUPT5H, and TRI-
AD3) had been shown to be highly expressed in previous
global gene expression surveys by either DNA microarrays
[20–25] or serial analysis of gene expression (http://
www.ncbi.nlm.nih.gov/SAGE/).
To obtain further information on the possible role of the
105 genes in the pathogenesis of pancreatic cancer, we
explored their functional characteristics by using the
SOURCE database (http://source.stanford.edu). According
to the SOURCE, 17 of 105 genes represented hypothetical
proteins and 21 were known genes or ESTs with no func-
tional annotation. A large fraction (78%) of the remaining 67
genes was involved in key cellular processes including signal
transduction (17 genes), protein processing (11), metabo-
lism (8), RNA processing (7), transcription (5), and DNA
replication (4).
Discussion
Pancreatic ductal adenocarcinoma is one of the top 10
causes of cancer death in industrialized countries, with over
40,000 deaths/year in Europe [35] and nearly 30,000 deaths/
year in the United States [1]. New methods for early detec-
tion, a better understanding of the biologic mechanisms
underlying cancer progression, and cancer-targeted treat-
ment modalities are urgently needed to reduce the mortality
from this lethal disease. The availability of global expression
and copy number platforms, such as cDNA microarrays, has
greatly facilitated the identification of novel tumor markers
in many cancer types. Here we used a 12,232-clone cDNA
microarray to search for genes that are activated by in-
creased copy number in pancreatic cancer. The main focus
of this study was to specifically identify genes whose over-
expression is caused by increased copy number (i.e., those
genes that are overexpressed only in cell lines with amplifi-
cation). Gene copy numbers were first determined by
performing CGH on the cDNA microarray, and subsequent
expression analysis using an identical cDNA microarray
permitted direct correlation between copy numbers and
expression levels on a gene-by-gene basis.
The high-resolution copy number analysis by CGH micro-
array revealed a total of 24 independent regions of copy
number increase in the 13 pancreatic cancer cell lines.
These included several chromosomal segments, such as
3q, 5p, 7q, 8q24, 11q13, 15q, 17q, 19q, and 20q, previously
implicated to be gained or amplified by chromosomal CGH or
fluorescence in situ hybridization in pancreatic cancer
[17,36,37]. In addition to validating data from these previous
studies, the CGH microarray analysis permitted mapping of
these copy number increases in much higher accuracy and
determination of the exact base-pair boundaries for each
aberration. For example, frequent copy number increases
were observed at three separate regions on chromosome 19
(19p13.3, 19q13.1, and 19q13.3). Although gains and ampli-
fications of 19q have been frequently reported both in
pancreatic cancer cell lines and primary pancreatic carcino-
mas [17,18,36], the CGH microarray analysis was able to
narrow down the affected regions to sizes of 130 kb, 2.9 Mb,
and 390 kb, respectively (Table 1). However, it has to be
noted that the size determination was fully dependent on the
local clone density on the microarray and therefore does not
necessarily correspond to the actual size of the amplicon.
The CGH microarray results obtained in this study con-
siderably advance our knowledge on common copy number
increases in pancreatic cancer and provide an improved
starting point for the identification of genes affected by such
copy number alterations. The subsequent expression survey
performed using an identical cDNA microarray revealed that
several genes located within the regions of increased copy
Figure 1. Gene copy number and expression analysis for chromosome 19 in
the Panc1 pancreatic cancer cell line by cDNA microarray. The copy number
ratios were plotted as a function of the position of the cDNA clones along
chromosome 19. In (A), individual data points were connected with a line. The
inset shows chromosomal CGH copy number ratio profile. In (B), individual
data points were color-coded according to cDNA expression ratios. The red
dots indicate overexpressed genes (the upper 7% of expression ratios) and
the green dots indicate underexpressed genes (lowest 7% of expression
ratios) in Panc1 cells.
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Table 2. List of 105 Genes with Statistically Significant Correlation (a < 0.05) between Gene Copy Number and Expression Level.
Gene Name Clone ID Locus a
EST 4541713 0.0035
CDC42-binding protein kinase beta (DMPK-like) 4582722 14q32.3 0.0045
POP7 (processing of precursor, Saccharomyces cerevisiae) homolog 3138336 7q22 0.0047
TRIAD3 protein* 3506949 7p22.2 0.0073
Hypothetical protein F231491 3504227 19q13.1 0.0083
Hypothetical protein DKFZp434H247 3010753 19q13.13 0.0104
Hypothetical protein FLJ10055 37134 17q24 0.0107
FK506-binding protein 4 (59 kDa) 3940730 12p13.33 0.0109
Hypothetical protein MGC3234 3504261 11p15.5 0.0111
Opioid growth factor receptor 3050950 20q13.3 0.0112
Tubulin, gamma 1 108377 17q21 0.0117
Mitochondrial ribosomal protein S12 2959394 19q13.1–q13.2 0.0118
Ribosomal protein L8 3506015 8q24.3 0.012
ATP-dependent RNA helicase 3687438 17q21.1 0.0123
EST 3503397 0.0125
b-1,3-Glucuronyltransferase 3 (glucuronosyltransferase I) 4299539 11q12.2 0.0127
EST 3543708 0.0129
p21 (CDKN1A)–activated kinase 4 3956856 19q13.1 0.0129
seryl-tRNA synthetase 2 3627808 19q13.13 0.0129
Metaxin 2 3542457 2q31.2 0.013
Sirtuin (silent mating type information regulation 2 homolog) 2* 2820929 19q13 0.013
Hypothetical protein FLJ20721 3544728 17q25.1 0.0132
Rho GDP dissociation inhibitor (GDI) b-* 3621138 12p12.3 0.0133
Ring finger protein 26 3028875 11q23 0.0133
KIAA0182 protein 2819273 16q24 0.014
Ribosomal protein S16 4310307 19q13.1 0.0141
MCM2 minichromosome maintenance deficient 2 3544403 3q21 0.0145
Cyclin D–binding myb-like transcription factor 1 3010038 7q21 0.0146
Hypothetical gene ZD52F10 3690018 19q13.11 0.015
RNA-binding motif protein 10 3163064 Xp11.23 0.015
Cleavage and polyadenylation specific factor 4 (30 kDa) 3356071 7q22.1 0.0152
Fibrillarin* 3504198 19q13.1 0.0153
Hypothetical protein FLJ14888 3141437 15q25.1 0.0157
Hypothetical protein MGC3040 3163990 3q21 0.0157
Suppressor of Ty 5 homolog (S. cerevisiae)* 3532191 19q13 0.0159
Succinate dehydrogenase complex, subunit A, flavoprotein (Fp) 3051442 5p15 0.0164
EST 4543771 0.0167
suppression of tumorigenicity 14 (colon carcinoma)* 2959447 11q24–q25 0.0173
GTP-binding protein 1 4127961 22q13.1 0.0175
Nuclear factor I/C (CCAAT-binding transcription factor) 4128493 19p13.3 0.0183
Similar to RIKEN cDNA 0610011N22 4334552 5p15.33 0.0185
Similar to RIKEN cDNA 1810006A16 gene 3942185 16q22.1 0.0186
Syndecan 1 3347793 2p24.1 0.0187
ADP ribosylation factor GTPase-activating protein 1 3162991 20q13.33 0.0191
Likely ortholog of mouse another partner for ARF 1 2822464 14q24.3 0.0192
Proteasome (prosome, macropain) 26S subunit, ATPase, 4* 4046205 19q13.11–q13.13 0.0202
EST 3628799 0.0203
Hypothetical protein MGC45840 3941077 11p15.5 0.0205
PCTAIRE protein kinase 1 3504276 Xp11.3–p11.23 0.0205
EST 3958225 0.0209
Hypothetical protein BC011824 3830276 19p13.3 0.021
DKFZP564B147 protein 2821721 Xq26.3 0.0213
Claudin 4* 3349211 7q11.23 0.022
EST, weakly similar to IDN3 protein, isoform B 3528352 0.0221
Major histocompatibility complex, class I, C 4249847 6p21.3 0.0225
Homo sapiens, clone IMAGE: 3029191, mRNA 3029191 7 0.0228
Inhibitor of kappa light polypeptide gene enhancer in B-cells 4651870 Xq28 0.0233
EST 3678374 0.0238
Proteasome (prosome, macropain) subunit, a type, 1 4105838 11p15.1 0.0241
Splicing factor, arginine/serine– rich 8 3352093 12q24.33 0.0243
EST 3503182 0.0244
KIAA0632 protein 3356434 7q22.1 0.0246
Putative translation initiation factor 2823520 17q21.2 0.0248
Ribonuclease H2, large subunit 3160621 19p13.12 0.0248
Adaptor-related protein complex 3, sigma 2 subunit 4139509 15q25.3 0.0254
Regulator of G-protein signalling 14 4547415 5q35.3 0.0254
KIAA1023 protein 37440 7p22.3 0.0257
Chromosome 20 open reading frame 126 4126826 20q11.21 0.0261
MLN51 protein 40515 17q11–q21.3 0.0271
Likely ortholog of mouse synembryn 3633778 11p15.5 0.0274
(continued on next page)
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number also showed elevated expression levels in the
pancreatic cancer cell lines. For example, several genes at
the 19q13.1 amplicon, such as FBL, PD2, SUPT5H, and
SARS2, were highly expressed in cell lines with increased
copy number. None of these genes has been previously
linked to cancer, but based on their function, FBL, which is
known to act in ribosomal RNA processing [38], and
SUPT5H, a putative modulator of chromatin structure [39],
might be implicated in cancer formation.
To evaluate the contribution of gene copy number to gene
expression level, a statistical procedure was applied to
systematically identify genes whose expression levels were
attributable to copy number increase across all 13 cell lines.
This analysis revealed 105 genes and included previously
described amplified genes as well as known oncogenes,
such as STK15, MLN51, RAB4A, and RELA. For example,
the STK15 gene (also called AURKA, aurora kinase A, and
BTAK) located at 20q13 is a putative oncogene that has
been shown to be amplified and overexpressed in many
human cancers [40–42]. STK15 is essential for normal
centrosome function and chromosome segregation [43]
and, recently, STK15 overexpression was shown to be
involved in degradation of the p53 tumor-suppressor protein,
leading to loss of p53 function [44].
Although gene copy number has been shown to be a
major determinant of gene expression level, a large fraction
of genes shows elevated expression levels without any
increase in gene copy number [33,45]. It was therefore
expected that our statistical approach identified an over-
lapping but a clearly separate set of genes than those
reported in studies where only expression levels were eval-
uated. A direct comparison between our data and previously
published global gene expression analyses [20–25] (http://
www.ncbi.nlm.nih.gov/SAGE/) revealed that 16% of the 70
known genes identified here have been previously reported
to be highly expressed in pancreatic cancer.
Most of the genes identified by the statistical approach in
this study had not been previously linked to pancreatic
cancer. However, some of them have been implicated in
tumor development. For example, p21-activated kinase 4
(PAK4) has been shown to regulate cell migration, cell
adhesion, and anchorage-independent growth both in hu-
man cancer cell lines and in fibroblasts, suggesting a central
role in oncogenic transformation and tumorigenesis [46–48].
To further clarify the possible roles of the 105 genes in
pancreatic cancer, we explored their functional character-
istics by using information from the SOURCE database
(http://source.stanford.edu). This analysis showed that 78%
of these genes were involved in functions, such as signal
transduction, transcription, and DNA replication, which are
essential for normal cellular processes but could also be
envisioned to have an impact on cancer development. Taken
Table 2. (Continued )
Gene Name Clone ID Locus a
Ubiquitin-specific protease 11 2961383 Xp11.23 0.0276
v-rel reticuloendotheliosis viral oncogene homolog A* 4547184 11q13 0.029
ATP synthase, H+ transporting, mitochondrial F0 complex 3826469 7q22.1 0.0291
Hypothetical protein MGC11242 3939938 17q21.32 0.0293
SIN3 homolog A, transcriptional regulator (yeast) 3604034 15q23 0.0293
Dual specificity phosphatase 3 3605391 17q21 0.0298
Asparagine synthetase 3010719 7q21.3 0.03
Copine I 4074508 20q11.21 0.0305
mitochondrial Ribosomal protein L45 3951804 17q21.2 0.0306
RPA-binding transactivator 3926937 19q13.13 0.0308
Hexosaminidase A (a polypeptide) 3353424 15q23–q24 0.0312
SPRY domain-containing SOCS box protein SSB-3 3342825 16p13.3 0.0319
Steroidogenic acute regulatory protein related 2823277 17q11–q12 0.0319
Chromosome 20 open reading frame 31 3051376 20q11.21 0.036
Enoyl coenzyme A hydratase 1, peroxisomal 4300082 19q13.1 0.036
WD repeat domain 5B 4097434 3q21.1 0.0367
Actin-related protein 2/3 complex, subunit 1B (41 kDa) 3138319 7q22.1 0.037
Epoxide hydrolase 1, microsomal (xenobiotic) 3547085 1q42.1 0.0371
Alkaline phosphatase, placental-like 2 4652865 2q37 0.0376
FtsJ homolog 2 (Escherichia coli) 3343278 7p22 0.0379
GTP-binding protein 5 (putative) 4564032 20q13.33 0.0386
Inactive progesterone receptor (23 kDa) 3353485 12q13.13 0.0387
EST 4634558 0.0401
FK506-binding protein 8 (38 kDa) 3543042 19p12 0.0421
Thyroid hormone receptor interactor 6 3610413 7q22 0.0421
Tripartite motif-containing 8 4561807 10q24.3 0.0444
RAB4A, member RAS oncogene family 3346455 1q42–q43 0.0455
Effector cell protease receptor 1 3351130 17q25 0.0459
MCM7 minichromosome maintenance deficient 7 (S. cerevisiae)* 4134871 7q21.3–q22.1 0.0462
ADP ribosylation factor-related protein 1 2989010 20q13.3 0.047
Chromosome 20 open reading frame 35 2959575 20q13.11 0.0473
KIAA0943 protein 3543516 2q37.3 0.0479
Serine/threonine kinase 15* 3532438 20q13.2–q13.3 0.048
Protein kinase, cAMP-dependent, regulatory, type I, b 3677877 7pter–p22 0.0485
Hypothetical protein FLJ10468 2822261 1p34.2 0.0495
*Genes previously shown to be overexpressed in pancreatic cancer by global expression profiling [20–25].
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together, the set of 105 genes identified in this study is likely
to represent genes that are activated by increased copy
number and might be actively involved in the pathogenesis
of pancreatic cancer. However, it has to noted that it will be
essential to validate the results obtained in this study by
using uncultured primary pancreatic tumors. Such validation
will also be essential to assess the possible clinical signifi-
cance of the genes implicated here.
In summary, our microarray-based genome-wide copy
number survey resulted in the identification of 24 indepen-
dent regions of copy number increase in 13 pancreatic
cancer cell lines. This approach allowed highly accurate
mapping of copy number increases with an average resolu-
tion of about 300 kb throughout the genome. Parallel ex-
pression analysis using an identical cDNA microarray
permitted direct comparison between gene copy numbers
and expression levels. A statistical evaluation disclosed a set
of 105 genes whose expression levels were directly linked to
copy number increase, indicating that they are activated
through amplification in pancreatic cancer. These results
implicate a set of genes that are likely to have an important
role in pancreatic cancer pathogenesis.
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